Background {#Sec1}
==========

Osteoarthritis (OA) is a complex arthritic condition characterized by progressive cartilage loss, synovitis, osteophyte formation, and subchondral sclerosis. It is a cause of important handicap among the elderly \[[@CR1], [@CR2]\]. It has been reported that there were nearly 85 million OA patients in the world in 2009, and it might increase to 122 million in 2017. Hence, it is an enormous burden on the national economy and healthcare system \[[@CR3], [@CR4]\]. OA is a multifactorial disease resulting from the combined influence of environmental factors and genes \[[@CR5]\]. Age, joint injury, and obesity are the major risk factors \[[@CR6], [@CR7]\]. Several studies have identified some genetic factors such as *ASPN* \[[@CR8]\], *FRZB* \[[@CR9]\], and *GDF5* \[[@CR10]\]. These three genes are involved in controlling growth and differentiation pathways \[[@CR11]\]. Many other polymorphisms have shown association to OA although the results are inconsistent. Further research is needed to replicate these findings and identify some new genetic factors \[[@CR12]\].

A disintegrin and metalloprotease (ADAM), a member of the Zn-dependent metzincin superfamily, is associated with many complex diseases such as heart disease, rheumatoid arthritis, Alzheimer's disease, and cancer \[[@CR13], [@CR14]\]. *ADAM12* may play an important role in chondrocyte proliferation, maturation, bone formation, and osteoclast differentiation \[[@CR15]--[@CR18]\]. ADAM12 is up-regulated in multinucleated giant cells surrounding loose hip implants and OA cartilage \[[@CR19], [@CR20]\]. Recently, promising but contradictory data have been published for the association of *ADAM12* with OA \[[@CR21]--[@CR25]\]. Poonpet et al*.* \[[@CR24]\] and Kerna et al. \[[@CR25]\] found that rs3740199 in *ADAM12* was associated with knee OA risk although the results were conflicting rather than conclusion \[[@CR12], [@CR23], [@CR26], [@CR27]\].

In the present study, a meta-analysis was performed to determine the overall association between *ADAM12* rs3740199 polymorphism and knee OA susceptibility and whether the association varies by ethnicity.

Methods {#Sec2}
=======

Literature search strategy {#Sec3}
--------------------------

To identify all relevant reports on rs3740199 polymorphism and knee OA risk, we performed a systematic search for all English language papers from PubMed (the last search update was April 14, 2017), using the key words "rs3740199" or "*ADAM12*," "polymorphism" or "polymorphisms" or "SNP," "osteoarthritis" or "OA". Additional eligible studies were identified by a manual search of the references of retrieved studies and review articles.

According to the following criteria, six studies were included in this meta-analysis: (1) was a cohort or case-control study; (2) was a study of the *ADAM12* rs3740199 polymorphism and knee OA risk; and (3) contained available genotype or allele frequency of rs3740199.

Data extraction {#Sec4}
---------------

Two of the investigators extracted all data independently according to the criteria described above. We developed a data extraction sheet including year of publication, the first author's name, OA type, country of origin, ethnicity, assessment of OA, genotyping method, source of control groups, genotype, and allele frequency. For studies contain the results from different knee OA types, each type was treated independently. Any controversies of the data were discussed within our research team and the authors reached a consensus on all items.

Statistical methods {#Sec5}
-------------------

Allele frequencies of the *ADAM12* rs3740199 polymorphism from the six eligible studies were calculated by the allele counting method respectively. Hardy--Weinberg equilibrium (HWE) was used to evaluate the deviation of data associated with the *ADAM12* rs3740199 SNP in the control groups using *χ* ^2^ test. The strength of association between the *ADAM12* rs3740199 polymorphism and knee OA susceptibility was evaluated by pooled odds ratios (ORs) and their 95% confidence intervals (CIs). The significance of the ORs and 95% CIs was determined by *Z* test. The pooled ORs and 95% CIs were performed for additive model (C vs. G), co-dominant model (CC vs. GG; CG vs. GG), dominant model (CC/CG vs. GG), and recessive model (CC vs. CG/GG). Stratified analysis was also performed by ethnicity.

We assessed the between-study heterogeneity using chi-square-based *Q* test. If the *P* value was less than 0.10, the heterogeneity was considered significant. We also used the *I* ^2^ statistic (*I* ^2^ = 100% × (*Q* − *df*)/Q) to quantify heterogeneity. *I* ^2^ greater than 50% indicated the presence of heterogeneity among studies. The fixed-effects model based on the Mantel--Haenszel method and the random-effects model based on the Dersimonian and Laird method were used to pool the data \[[@CR28]\]. The random-effects model was more appropriate in the presence of heterogeneity; otherwise, the two methods provide similar results.

In meta-analysis, publication bias is also a concern. To test for publication bias, both Egger's and Begg's test are commonly used \[[@CR29]\]. In this study, publication bias was evaluated by funnel plot and the linear regression asymmetry test.

All analyses were carried out using Stata software version 8.2 (Stata Corporation, College Station, TX, USA). All tests were two-sided.

Results {#Sec6}
=======

Characteristics of the included studies {#Sec7}
---------------------------------------

Eleven relevant studies identified and screened. Four studies were added through manual search of the reference lists of retrieved studies. Nine of the 15 studies were excluded: three not polymorphism, one not for OA research, and five no useable data reported. A total of six reports were identified \[[@CR12], [@CR23]--[@CR27]\]. Among these, Rodriguez-Lopez et al. reported six sample collections \[[@CR12]\] while Kerna et al. included subjects with tibiofemoral knee OA (TFOA) and patellofemoral knee OA (PFOA) \[[@CR25]\], they were considered as independent studies. Finally, nine studies with 2185 cases and 3716 controls were included in the present meta-analysis. The detailed study flow chart was illustrated in Fig. [1](#Fig1){ref-type="fig"}. Characteristics of the nine studies were listed in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Of eligible studies, four and five studies were conducted in Asian and European populations respectively.Fig. 1Studies identified with criteria for inclusion and exclusion Table 1Characteristics of literatures included in this meta-analysisYearFirst authorOA typeCountryEthnicityAssessment of OAGenetypingSource of controlsCasesControls2009J. Rodriguez-LopezTKRSpainEuropeanK/L scoreMultiplex single-base extensionPB262294TKRUKEuropeanK/L scoreMultiplex single-base extensionPB360698TKRGreeceEuropeanK/L scoreMultiplex single-base extensionPB1591932009I. KernaTFOAEstonianEuropeanOA scorePCR-RFLPPB66123PFOAEstonianEuropeanOA scorePCR-RFLPPB97922012Min-Ho ShinKnee OAKoreaAsianK/L scoreTaqManPB72517372014Suliang LouKnee OAChinaAsianK/L scoreTaqManPB1521792015LinWangKnee OAChinaAsianK/L scoreiMLDRPB1642002016Thitiya PoonpetKnee OAThaiAsianK/L scoreHRM analysisPB200200*K/L score* Kellgren--Lawrence score, *PB* population based, *TKR* total knee replacement, *TFOA* tibiofemoral knee OA, *PCR-RFLP* polymerase chain reaction-restriction fragment length polymorphism, *PFOA* patellofemoral knee OA, *iMLDR* improved multiplex ligase detection reaction, *HRM* high resolution melting Table 2Distributions of ADAM2 rs3740199 genotypes and alleles among cases and controlsYearFirst authorCaseControlCaseControlHWE in controlCCGCGGCCGCGGCGCG2009J. Rodriguez-Lopez^a^NANANANANANA290234327261NA2009J. Rodriguez-Lopez^a^NANANANANANA370350744652NA2009J. Rodriguez-Lopez^a^NANANANANANA180138239147NA2009I. Kerna^a^283266546128844176700.3662009I. Kerna^a^5334104143814054125590.4852012Min-Ho Shin147364214350863524658792156319110.8762014Suliang Lou3278424293441421621771810.62015LinWang36844447102511561721962040.7732016Thitiya Poonpet561024246100542141861922080.982*HWE* Hardy--Weinberg equilibrium, *NA* data not available^a^An independent study in one article

Quantitative synthesis {#Sec8}
----------------------

The details of meta-analysis for *ADAM12* rs3740199 polymorphism with knee OA risk are shown in Table [3](#Tab3){ref-type="table"}.Table 3Meta-analysis for the ADAM2 rs3740199 polymorphism and knee OA riskPopulationComparison (*N* ^a^)Test of associationTest of heterogeneityOR (95% CI)*P* ^b^*P* ^c^*I* ^2^ (%)OverallC vs. G (12)0.983 (0.910--1.061)0.6570.4900.0CC vs. GG (6)1.033 (0.851--1.255)0.7400.6810.0CG vs. GG (6)1.030 (0.877--1.209)0.7210.7700.0CC/CG vs. GG (6)1.031 (0.886--1.201)0.6900.7680.0CC vs. CG/GG (6)1.017 (0.868--1.190)0.8370.3648.1Ethnicity AsianC vs. G (4)1.020 (0.924--1.127)0.6890.3980.0CC vs. GG (4)1.040 (0.850--1.272)0.7030.3900.4CG vs. GG (4)1.035 (0.878--1.221)0.6810.7090.0CC/CG vs. GG (4)1.036 (0.887--1.211)0.6560.5020.0CC vs. CG/GG (4)1.017 (0.858--1.207)0.8430.6420.0 EuropeanC vs. G (8)0.930 (0.825--1.049)0.2390.5380.0CC vs. GG (2)0.950 (0.453--1.992)0.8910.8090.0CG vs. GG (2)0.927 (0.446--1.930)0.8400.3016.6CC/CG vs. GG (2)0.940 (0.465--1.901)0.8640.7130.0CC vs. CG/GG (2)0.998 (0.445--2.237)0.9960.05273.4*OR* odds ratio, *CI* confidence interval^a^Number of comparison^b^ *P* values for within group differences were determined by *Z* test^c^ *P* value of *Q* test for heterogeneity test

Overall population {#Sec9}
------------------

Nine separate studies with a total sample size of 2185 cases and 3716 controls had available data for analyzing the association of *ADAM12* rs3740199 polymorphism and knee OA risk. No significant association was found in all genetic models (C vs. G, OR = 0.983, 95% CI = 0.910--1.061; CC vs. GG, OR = 1.033, 95% CI = 0.851--1.255; CG vs. GG, OR = 1.030, 95% CI = 0.877--1.209; CC/CG vs. GG, OR = 1.031, 95% CI = 0.886--1.201; CC vs. qECG/GG, OR = 1.017, 95% CI = 0.868--1.190) (Table [3](#Tab3){ref-type="table"}).

Subgroup analysis by ethnicity {#Sec10}
------------------------------

No significant association was found in all genetic models among Asian population (C vs. G, OR = 1.020, 95% CI = 0.924--1.127; CC vs. GG, OR = 1.040, 95% CI = 0.850--1.272; CG vs. GG, OR = 1.035, 95% CI = 0.878--1.221; CC/CG vs. GG, OR = 1.036, 95% CI = 0.887--1.211; CC vs. CG/GG, OR = 1.017, 95% CI = 0.858--1.207). No significant association was found in European population either.

Heterogeneity and publication bias {#Sec11}
----------------------------------

The between-study heterogeneity of the *ADAM12* rs3740199 polymorphism was not found in all subjects, and thus, the meta-analysis of the *ADAM12* rs3740199 polymorphism was performed using a fixed-effects model for all subjects except for the recessive model in European population, which was analyzed using a random-effects model (*I* ^2^ = 73.4%) (Table [3](#Tab3){ref-type="table"}).

In this study, publication bias was evaluated by funnel plot and the linear regression asymmetry test. As shown in Fig. [2](#Fig2){ref-type="fig"}, the shape of the funnel did not reveal obvious asymmetry. Then, Egger's test was then performed to estimate the funnel plot symmetry. The results still did not show any evidence of publication bias (*t* = −0.40, *P* = 0.699 for C vs. G).Fig. 2Begg's funnel plot for publication bias test (C versus G). Each point represented a separate study for the indicated association. *logor* natural logarithm of OR. *Horizontal line* mean effect size

Discussion {#Sec12}
==========

OA is well recognized as a multifactorial disease. In addition to age, sex, trauma, and body weight, genetic factors are also strong determinants of this disease \[[@CR30]\]. More than 50% of the OA cases can be attributed to genetic factors, demonstrated by twins and family studies \[[@CR31]\]. It is suggested that OA of the hand, spine, hip, and knee are all heritable \[[@CR32]\]. Recently, genetic studies have found many genes are contributing to OA, although with relatively modest effect \[[@CR33]\]. These observations have encouraged us to search for more responsible genes. Many genes have been studied and the *ADAM12* gene is one of the possible candidate genes for OA \[[@CR12], [@CR23]--[@CR27]\]. Some investigations suggested a regulatory role of *ADAM12* in chondrocyte proliferation, maturation, bone formation, and osteoclast differentiation \[[@CR15]--[@CR18]\]. Association studies have been arranged to investigate the role of a nonsynonymous polymorphism (rs3740199) in the second exon of *ADAM12* in knee OA risk that has been reported to date \[[@CR12], [@CR21], [@CR25], [@CR26], [@CR34]\]. However, these findings have been inconsistent and contradictory.

Meta-analysis is a suitable method to combine the results of individual studies, overcome the disadvantages of a single study, and increase the statistical power. The present study was to investigate and update the results associating the *ADAM12* rs3740199 polymorphism with knee OA risk in different ethnic populations. To our knowledge, the present study is the first meta-analysis which estimated the association between *ADAM12* rs3740199 and knee OA susceptibility. No significant association of *ADAM12* rs3740199 polymorphisms with knee OA risk was demonstrated in our study. We also failed to find the association between knee OA and the *ADAM12* polymorphism in Asian and European population. No heterogeneity was found in overall population and Asian population, while high heterogeneity was seen in the recessive model in European population.

Association studies with complex outcomes for detecting genetic variants must be considered with caution because the results may be influenced by many factors. Our present study showed a lack of association between the *ADAM12* rs3740199 polymorphism and knee OA risk, which is not consistent with the association or functional studies of the *ADAM12* polymorphism. However, epidemiologic results are always different from the functional studies because OA is a multifactorial disease influenced by different genetic backgrounds, multiple genes, and environmental factors. Our negative results of the *ADAM12* polymorphism may also be due to type II error. In recent years, some genome-wide association studies (GWAS) have already reported *GDF5*, *BTNL2*, *DUS4L*, *COG5*, *SENP6*, and *FILIP1* as OA candidate genes \[[@CR35], [@CR36]\]. However, the *ADAM12* polymorphism has not been confirmed in these GWAS \[[@CR35], [@CR36]\].

Our results are consistent with some studies that also failed to detect association between rs3740199 and OA susceptibility in either male or female patients \[[@CR12], [@CR23], [@CR26], [@CR27]\]. On the other hand, Poonpet et al. reported the rs3740199 polymorphism was associated with knee OA risk, while the effect was only found in Thai male patients \[[@CR24]\]. The C allele of rs3740199 was found to be associated with OA in female patients in the UK \[[@CR21]\]. Kerna et al. found significant association between *ADAM12* rs3740199 and PFOA in male patients \[[@CR25]\]. The reason for the contradictory results remain unclear, but the differences in study populations including age, gender, sample size, and disease severity may play an important role. In the meanwhile, the environmental factors in each sample such as lifestyles, diets, and selected physical activity may also affect the association between rs3740199 polymorphism and OA risk. Lastly, each population has their own gene pool, so it is not surprising that there are differences in the distributions of *ADAM12* rs3740199 genotypes and alleles from subjects with different ethnicities.

Some limitations of this meta-analysis should also be noted. First, the potential confounding factors (such as age, gender) were not adjusted in the present study. Second, the gene-environment interactions and the effect of gene-gene should also be considered because they might influence the biological effects of the polymorphisms of the *ADAM12* gene. Third, because it was difficult to get all full papers published in different languages, we only included six studies published in English language. Fourth, the included subjects were not adequate to confirm a robust conclusion and the association should be resolved by larger studies.

Conclusions {#Sec13}
===========

In conclusion, this meta-analysis did not reveal any association between the *ADAM12* rs3740199 polymorphism and knee OA risk. Additional larger studies are needed to confirm our findings in the future.
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